CN-122005556-A - Use and composition of iron transporter inhibitors (VIT-2763)

Abstract

The application relates to the technical field of antitumor drugs, and particularly discloses an application and a composition of an iron transport protein inhibitor (VIT-2763). The application provides an application of an iron transport protein inhibitor VIT-2763 in preparing a medicament for preventing and treating tumor metastasis. The iron transport protein inhibitor VIT-2763 can obviously inhibit liver metastasis of colorectal cancer and has potential as an anti-colorectal cancer liver metastasis drug. Meanwhile, the application also provides a composition for resisting colorectal cancer liver metastasis, which comprises an iron transport protein inhibitor VIT-2763 and oxaliplatin, and when the iron transport protein inhibitor VIT-2763 and the oxaliplatin are used in combination, the drug resistance of colorectal cancer cells to the oxaliplatin can be improved, the sensitivity of liver metastasis colorectal cancer cells to the oxaliplatin can be obviously improved, the treatment effect of resisting colorectal cancer liver metastasis can be synergistically enhanced, and the technical problem that the existing treatment means lack specific intervention means for colorectal cancer liver metastasis can be solved.

Inventors

• ZENG ZHICHENG
• HUANG HAO
• LIU YE
• PENG SHUNLI

Assignees

• 中山大学附属第五医院

Dates

Publication Date

20260512

Application Date

20260401

Claims (10)

1. 1. The use of an iron transport protein inhibitor VIT-2763 for the manufacture of a medicament for the prevention and treatment of tumour metastasis.
2. 2. The use according to claim 1, wherein the tumour is colorectal cancer.
3. 3. The use according to claim 1, wherein the tumor metastasis is liver metastasis.
4. 4. The use according to claim 1, wherein the medicament down-regulates expression of FPN in oxaliplatin resistant cells.
5. 5. A medicament for preventing and treating tumor liver metastasis, which is characterized by comprising an iron transporter inhibitor VIT-2763.
6. 6. A composition for preventing and treating tumor liver metastasis, comprising an iron transporter inhibitor VIT-2763 and oxaliplatin.
7. 7. Use of a medicament according to claim 5 or a composition according to claim 6 for the preparation of a medicament for the prevention and treatment of tumour metastasis.
8. 8. The use according to claim 7, wherein the tumour is colorectal cancer.
9. 9. The use according to claim 7, wherein the tumor metastasis is liver metastasis.
10. 10. The use according to claim 7, wherein the agent down regulates expression of FPN in oxaliplatin resistant cells.

Description

Use and composition of iron transporter inhibitors (VIT-2763) Technical Field The application relates to the technical field of antitumor drugs, in particular to application and a composition of an iron transport protein inhibitor VIT-2763. Background Colorectal cancer is one of the global high-grade malignant tumors, and liver metastasis is a major cause of poor prognosis and death in colorectal cancer patients. Clinical data indicate that about 70% of colorectal cancer-related deaths are caused by liver metastasis, which occurs in nearly half of patients at the time of initial diagnosis. Even if the liver metastasis is subjected to surgical excision and auxiliary chemotherapy after the operation, the survival rate of the patients in 5 years is only 20% -50%, and the overall treatment effect is still not ideal. Currently, oxaliplatin-based combination chemotherapy is the first line standard regimen for clinical treatment of metastatic colorectal cancer. However, a key problem is common in clinical practice, namely that colorectal cancer primary foci and liver metastases often show significantly different therapeutic responses to the same chemotherapy regimen, which indicates that the colorectal cancer primary foci and liver metastases have obvious heterogeneity in terms of molecular regulation, microenvironment characteristics, drug resistance mechanisms and the like. The existing clinical diagnosis and treatment mode generally adopts a homogenization treatment strategy for a primary focus and a metastasis focus, and cannot implement accurate intervention aiming at the special biological characteristics of the liver metastasis focus, so that the further improvement of the overall treatment effect of colorectal cancer liver metastasis is greatly restricted. The theory of "seed-soil" for tumor metastasis suggests that disseminated tumor cells need to be in a suitable remote organ microenvironment to complete colonization and proliferation. Recent studies have shown that remodelling of the microenvironment of the distant organs is a key factor in determining the survival, colonization and therapeutic resistance of disseminated tumor cells. However, the specific molecular mechanisms of adaptation, colonization and chemotherapy resistance of colorectal cancer cells in the liver microenvironment are still unknown, and corresponding intervention targets and treatment strategies are still lacking. Therefore, the key regulation mechanism of colorectal cancer liver metastasis is deeply revealed, and the development of novel targeted intervention drugs has important clinical value for improving prognosis of metastatic colorectal cancer patients. Disclosure of Invention Accordingly, the present application is directed to the use and composition of an iron transporter inhibitor VIT-2763 for solving the technical problem of lack of specific intervention means for liver metastasis in the prior art. In order to achieve the technical aim, the application provides an application of an iron transport protein inhibitor VIT-2763 in preparing medicines for preventing and treating tumor metastasis. Further, the tumor is colorectal cancer. Further, tumor metastasis is liver metastasis. Further, the drug down regulates the expression of FPN in oxaliplatin resistant cells. The application provides a medicine for preventing and treating tumor liver metastasis, which comprises an iron transport protein inhibitor VIT-2763. The application provides a composition for preventing and treating tumor liver metastasis, which comprises an iron transport protein inhibitor VIT-2763 and oxaliplatin. Further, the preparation method is used for preparing the medicine for preventing and treating tumor metastasis. Further, the tumor is colorectal cancer. Further, tumor metastasis is liver metastasis. Further, the drug down regulates the expression of FPN in oxaliplatin resistant cells. In summary, the application provides an application of an iron transport protein inhibitor VIT-2763 in preparing medicines for preventing and treating tumor metastasis. The iron transport protein inhibitor VIT-2763 can obviously inhibit liver metastasis of colorectal cancer and has potential as an anti-colorectal cancer liver metastasis drug. The application also provides a pharmaceutical composition for resisting colorectal cancer liver metastasis, and the active ingredients of the pharmaceutical composition comprise an iron transporter inhibitor VIT-2763 and oxaliplatin. When the iron transport protein inhibitor VIT-2763 is used in combination with oxaliplatin, the drug resistance of colorectal cancer cells to oxaliplatin can be improved, the sensitivity of liver metastasis colorectal cancer cells to oxaliplatin is obviously improved, the curative effect of resisting colorectal cancer liver metastasis is synergistically enhanced, and a new strategy and selection are provided for clinical treatment of colorectal cancer liver metastasis. Compared with the prior art, t